eligibility_summary
Adults 18–75 with histologically confirmed advanced colorectal cancer, BRAF V600E+, failed/intolerant to 1st-line, ECOG PS 0–1, measurable disease, LVEF ≥60%, adequate organs, survival ≥12 wks, contraception and consent required. Exclude: other recent cancers, concurrent trials, prior BRAF/MEK or checkpoint/T-cell therapies, recent immunomodulators/steroids, active autoimmune disease, transplants, severe mAb allergy, unresolved AEs, HIV, active HBV/HCV, live vaccine, pregnancy/lactation, serious illness, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, single-arm study in BRAF V600E–mutated advanced colorectal cancer testing: 1) Cetuximab (chimeric IgG1 anti-EGFR monoclonal antibody) that blocks EGFR ligand binding and downstream signaling and can mediate ADCC, 2) Dabrafenib (oral small-molecule BRAF V600E inhibitor) suppressing RAF/MEK/ERK (MAPK) signaling, 3) Tislelizumab (anti-PD-1 IgG4 monoclonal antibody engineered to minimize FcγR binding) restoring T-cell antitumor activity. Targets: EGFR on tumor cells, mutant BRAF/MAPK pathway, PD-1 on T cells (checkpoint). Potential NK-cell ADCC via cetuximab.